To include your compound in the COVID-19 Resource Center, submit it here.

Genasense G3139: Phase I

GNTA reported that in a 10-patient dose escalation Phase I trial of

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE